Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.

by Cindy Tamminga, Martha Sedegah, David Regis, Ilin Chuang, Judith E Epstein, Michele Spring, Jose Mendoza-Silveiras, Shannon McGrath, Santina Maiolatesi, Sharina Reyes, Victoria Steinbeiss, Charlotte Fedders, Kathryn Smith, Brent House, Harini Ganeshan, Jennylynn Lejano, Esteban Abot, Glenna J Banania, Renato Sayo, Fouzia Farooq, Maria Belmonte, Jittawadee Murphy, Jack Komisar, Jackie Williams, Meng Shi, Donald Brambilla, Nalini Manohar, Nancy O Richie, Chloe Wood, Keith Limbach, Noelle B Patterson, Joseph T Bruder, Denise L Doolan, C Richter King, Carter Diggs, Lorraine Soisson, Daniel Carucci, Gail Levine, Sheetij Dutta, Michael R Hollingdale, Christian F Ockenhouse, Thomas L Richie
Published 2011-01-01